Bioprexum Plus Dosage/Direction for Use

Posology: One BIOPREXUM Plus 5 mg/1.25 mg film-coated tablet per day as a single dose, preferably to be taken in the morning, and before a meal.
When possible individual dose titration with the components is recommended. BIOPREXUM Plus 5 mg/1.25 mg film-coated tablet should be used when blood pressure is not adequately controlled on BIOPREXUM Plus 2.5 mg/0.625 mg film-coated tablet (where available). When clinically appropriate, direct change from monotherapy to BIOPREXUM Plus 5 mg/1.25 mg film-coated tablet may be considered.
Special populations: Elderly (see "Precautions"): Treatment should be initiated after considering blood pressure response and renal function.
Renal impairment (see "Precautions"): In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.
In patients with moderate renal impairment (creatinine clearance 30-60 mL/min), it is recommended to start treatment with the adequate dosage of the free combination.
In patients with creatinine clearance greater than or equal to 60 mL/min, no dose modification is required. Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see "Contraindications", "Precautions" and "Pharmacology: Pharmacokinetics under Actions"): In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population: The safety and efficacy of perindopril arginine/indapamide in the paediatric population have not yet been established. No data are available.
BIOPREXUM Plus 5 mg/1.25 mg should not be used in children and adolescents.
Method of administration: Oral use.